drugset
drugset / Trial / NCT03071094

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

NCT03071094 ↗

Phase 1/2 Terminated 14 enrolled Transgene
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Timeline

Start
2017-07-27
Primary completion
2020-09-30
Completion
2021-02-03

Outcome

Outcome not reported

Stopped: “The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459).”

Drugs

EvaluationDrugModalityDoseRoute
Subject JX-594 Other / unclassified 1e+09 unknown Other
Subject Nivolumab Monoclonal antibody — Intravenous

Indications

hepatocellular carcinoma